270 related articles for article (PubMed ID: 21328566)
21. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
[TBL] [Abstract][Full Text] [Related]
22. [Diagnosis, histopathologic grading and prognostic moleculer marker analysis in patients with pancreatic neuroendocrine neoplasm].
Bao F; Chen GR; Hui P; Cai GP
Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):426-32. PubMed ID: 24060085
[No Abstract] [Full Text] [Related]
23. Lymphoid Enhancer Binding Factor 1 (LEF1) and Paired Box Gene 8 (PAX8): A Limited Immunohistochemistry Panel to Distinguish Solid Pseudopapillary Neoplasms and Pancreatic Neuroendocrine Tumors.
Lu H; Allende D; Liu X; Zhang Y
Appl Immunohistochem Mol Morphol; 2020; 28(10):776-780. PubMed ID: 32723981
[TBL] [Abstract][Full Text] [Related]
24. Expression of Sex Determining Region Y-Box 2 and Pancreatic and Duodenal Homeobox 1 in Pancreatic Neuroendocrine Tumors.
Akiyama T; Shida T; Yoshitomi H; Takano S; Kagawa S; Shimizu H; Ohtsuka M; Kato A; Furukawa K; Miyazaki M
Pancreas; 2016 Apr; 45(4):522-7. PubMed ID: 26491904
[TBL] [Abstract][Full Text] [Related]
25. Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility.
Schmitt AC; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Aug; 118(4):196-202. PubMed ID: 20731005
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
[TBL] [Abstract][Full Text] [Related]
27. Role of PAX-8, CD5, and CD117 in distinguishing thymic carcinoma from poorly differentiated lung carcinoma.
Asirvatham JR; Esposito MJ; Bhuiya TA
Appl Immunohistochem Mol Morphol; 2014; 22(5):372-6. PubMed ID: 23958552
[TBL] [Abstract][Full Text] [Related]
28. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
29. Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?
Rebours V; Cordova J; Couvelard A; Fabre M; Palazzo L; Vullierme MP; Hentic O; Sauvanet A; Aubert A; Bedossa P; Ruszniewski P
Dig Liver Dis; 2015 Nov; 47(11):973-7. PubMed ID: 26169284
[TBL] [Abstract][Full Text] [Related]
30. Targeting pancreatic expressed PAX genes for the treatment of diabetes mellitus and pancreatic neuroendocrine tumors.
Martin-Montalvo A; Lorenzo PI; López-Noriega L; Gauthier BR
Expert Opin Ther Targets; 2017 Jan; 21(1):77-89. PubMed ID: 27841034
[TBL] [Abstract][Full Text] [Related]
31. Reliability of PAX8 in clinical practice to accurately determine primary site of origin in female pelvic or abdominal lesions.
Roma AA; Downs-Kelly E
Ann Diagn Pathol; 2014 Aug; 18(4):227-31. PubMed ID: 24857336
[TBL] [Abstract][Full Text] [Related]
32. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology.
Chatzipantelis P; Konstantinou P; Kaklamanos M; Apostolou G; Salla C
Cancer; 2009 Jun; 117(3):211-6. PubMed ID: 19350669
[TBL] [Abstract][Full Text] [Related]
33. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study.
Ozcan A; Shen SS; Hamilton C; Anjana K; Coffey D; Krishnan B; Truong LD
Mod Pathol; 2011 Jun; 24(6):751-64. PubMed ID: 21317881
[TBL] [Abstract][Full Text] [Related]
34. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
[TBL] [Abstract][Full Text] [Related]
35. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
36. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis.
Weissferdt A; Moran CA
Am J Surg Pathol; 2011 Sep; 35(9):1305-10. PubMed ID: 21836478
[TBL] [Abstract][Full Text] [Related]
37. NKX6-1 Is a Novel Immunohistochemical Marker for Pancreatic and Duodenal Neuroendocrine Tumors.
Tseng IC; Yeh MM; Yang CY; Jeng YM
Am J Surg Pathol; 2015 Jun; 39(6):850-7. PubMed ID: 25871618
[TBL] [Abstract][Full Text] [Related]
38. PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases.
Fujiwara M; Taube J; Sharma M; McCalmont TH; Kim J
J Cutan Pathol; 2010 Sep; 37(9):938-43. PubMed ID: 20492080
[TBL] [Abstract][Full Text] [Related]
39. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.
Yemelyanova A; Gown AM; Wu LS; Holmes BJ; Ronnett BM; Vang R
Int J Gynecol Pathol; 2014 Sep; 33(5):492-9. PubMed ID: 25083965
[TBL] [Abstract][Full Text] [Related]
40. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]